Immuneid Announces Close Of $50 Million Series A Financing To Develop Precision Immunology Therapeutics

Jun 23, 2021•about 4 years ago

Amount Raised

$50 Million

Round Type

series a

Cambridge

Description

ImmuneID, Inc., a precision immunology company employing a proprietary platform to identify and therapeutically target antibody interactions that drive immune diseases, today announced that it has raised $50 million in Series A financing. This Series A financing brings the total amount raised by ImmuneID since its December 2020 launch to over $70 million. Proceeds from the financing will be used to advance the development of therapeutic candidates to treat autoimmune diseases, severe allergies, cancer and infectious diseases.

Company Information

Company

Immune

Location

Cambridge, Maryland, United States

About

ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases. Based on technology developed by scientific founders Stephen Elledge (Harvard), Ben Larman (Johns Hopkins), and Tomasz Kula (Harvard), we are employing our massively parallel, multiplexed and unbiased systems to develop therapeutics for autoimmunity, severe allergy, oncology and infectious disease. ImmuneID was founded in 2020 by Longwood Fund and is headquartered in Cambridge, MA.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Immuneid Announces Close Of $50 Million Series A Financing To Develop Precision Immunology Therapeutics

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information